SCHEMBL460948

SCHEMBL460948

COC(=O)C(OC(C)(C)C)c1c(C)nc2c(Cl)c(C)nn2c1-c1ccc2c(c1)CCCO2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.40
P2RX3 P56373 4/20 0.37
PSIP1 O75475 1/20 0.36
CYP3A4 P08684 1/20 0.36
NPC1 O15118 1/20 0.33
CLK1 P49759 1/20 0.33
RAB9A P51151 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
RIPK1 Q13546 1/20 0.32
NOTUM Q6P988 1/20 0.32
PIR O00625 1/20 0.32
HSF1 Q00613 1/20 0.32
FABP3 P05413 2/20 0.31
FABP4 P15090 2/20 0.31
FABP5 Q01469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL462405 0.92 NR1I2 (0.47) NR1I2P2RX3PSIP1CYP3A4PDE4A
SCHEMBL12986517 0.84 NR1I2 (0.38) NR1I2P2RX3PSIP1CYP3A4NPC1
SCHEMBL461603 0.83 NR1I2 (0.39) NR1I2P2RX3PSIP1CYP3A4NPC1
SCHEMBL462760 0.83 NR1I2 (0.44) NR1I2PSIP1CYP3A4NPC1CLK1
SCHEMBL10175634 0.82 NR1I2 (0.51) NR1I2P2RX3PSIP1CYP3A4NPC1
SCHEMBL13278040 0.79 PSIP1 (0.43) NR1I2P2RX3PSIP1CYP3A4NPC1
SCHEMBL461001 0.79 NR1I2 (0.61) NR1I2CYP3A4
SCHEMBL14576865 0.77 PSIP1 (0.44) NR1I2P2RX3PSIP1CYP3A4NPC1
SCHEMBL14576500 0.77 PSIP1 (0.44) NR1I2P2RX3PSIP1CYP3A4NPC1
SCHEMBL14576499 0.77 PSIP1 (0.44) NR1I2P2RX3PSIP1CYP3A4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
EP-2614064-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2013-07-17 EP disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS NR1I2 3085/4885P2RX3 4433/4885PSIP1 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.